Document is current
Any future updates will be listed below
-
Authors
Cattani, Vitória Berg https://orcid.org/0000-0002-8148-403X
Jalil, Emilia Moreira https://orcid.org/0000-0001-6017-5660
Eksterman, Leonardo
Torres, Thiago https://orcid.org/0000-0002-2557-601X
Wagner Cardoso, Sandra https://orcid.org/0000-0001-5230-0003
Castro, Cristiane R. V. https://orcid.org/0000-0001-5767-1452
Monteiro, Laylla https://orcid.org/0000-0003-4907-0459
Wilson, Erin https://orcid.org/0000-0002-0237-495X
Bushman, Lane
Anderson, Peter https://orcid.org/0000-0002-1200-8494
Veloso, Valdilea Gonçalves https://orcid.org/0000-0002-6622-3165
Grinsztejn, Beatriz https://orcid.org/0000-0003-3692-5155
Estrela, Rita https://orcid.org/0000-0002-5653-1690
,
Hoagland, Brenda
Moura, Isabele
Waite, Daniel M. McMahon
Vieira, Desirée
Granjeiro, José Roberto
Freitas, Josias
Santos, Toni
Fernandes, Nilo
Nazer, Sandro
Marins, Luana M. S.
Ribeiro, Valéria R. T.
Silva, Robson P. N.
Costa, Giovanna G.
Vieira, Ana Carolina
Bastos, Renata A
Alves, Aline
Krstic, Tania
Ferreira, Ana Cristina G.
Derrico, Monica
Kamel, Luciana
Jalil, Cristina M.
Netto, Eduardo Carvalheira
de Sousa, Marcos Davi G.
Leite, Pedro
Mattos, Kim Geraldo
Felix, Jessica Bezerra
Baião, Tamires Vilela
Hottz, Gisele
Maia, Natália Gomes
da Silva, Tamiris Paixão
Ramos, Michelle
Porto, Tiago
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03220152 at ClinicalTrials.govDocuments that mention this clinical trial
Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions
https://doi.org/10.1007/s40262-023-01248-0
-
Funding
Funding for this research was provided by:
Brazilian Ministry of Health (#01/2013 BRA/K57)
Secretaria de Vigilância em Saúde (#281/2013)
- License Information
-
More Information
Article History
Accepted: 29 March 2023
First Online: 1 June 2023
Declarations
:
: This work was supported by the Brazilian Ministry of Health (Brasília, Brazil; #01/2013 BRA/K57), <i>Secretaria de Vigilância em Saúde</i> (SVS; #281/2013), and partially supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—CAPES—Finance Code 001. Gilead Sciences donated the study drug and covered costs related to drug concentration assessment, but had no role in study design, collection, analysis, and interpretation of data, writing of the manuscript, or the decision to submit the manuscript for publication.
: Peter Anderson has received consulting fees from Gilead, Merck, and ViiV, and research funding paid to his institution from Gilead. All other authors declare no competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. It was approved by the Evandro Chagas National Institute of Infectious Diseases-FIOCRUZ Institutional Review Board. The PrEParadas study is registered with clinicaltrials.gov (NCT03220152). Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: Data are available from the corresponding author upon request.
: Not applicable.
: EMJ, VGV, BG and RE conceived the study and interpreted the findings. EMJ, BG, RE and VBC drafted the manuscript. VBC did the statistical analyses with aid from EMJ and RE. TT, SWC, LE, CRVC and LM helped with data acquisition, interpretation of the findings, and drafting the manuscript. VGV, PA, LB and EW were involved in revising the manuscript for important intellectual content. All authors read and approved the final manuscript.
